HCW Biologics regained Nasdaq bid-price compliance, faces monitoring period
HCW Biologics received written notice on June 29, 2026, that the Nasdaq Hearings Panel found the company regained compliance with Listing Rule 5550(a)(2), the…
Company
SEC filing news and material events for HCW Biologics Inc., briefed from primary-source filings.
1 story
HCW Biologics received written notice on June 29, 2026, that the Nasdaq Hearings Panel found the company regained compliance with Listing Rule 5550(a)(2), the…